Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Ultra-high purity surfactant for biologics and parenteral drug formulations
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The company’s largest center for medical device applications, serving the entire Asian market
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
Increases speed to market for drug developers working on nucleic acid therapeutics
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Yann d’Hervé takes over responsibility for the Health Care business at Evonik, effective July 1
New solvent-free micronization technology expanded at the Darmstadt site in Germany
Subscribe To Our Newsletter & Stay Updated
